[Method] HOPE FOR GRAYCELS, immunosuppresants drugs completely reverse graying

B

brrrap

Iron
Joined
Sep 26, 2018
Posts
126
Reputation
166
Credit to @MaleSuicideIsAGoodThing

Importance New targeted therapies for cancer have been released in recent years, opening new horizons in the treatment of patients with cancer. However, their related adverse events (AE) are not fully characterized. Hair repigmentation (HR) is a nondescribed effect secondary to anti–programmed cell death 1 (anti–PD-1) and anti–programmed cell death ligand 1 (anti–PD-L1 ) therapy for treatment of lung cancer (LC), in opposition to the vitiligo reactions that develop during melanoma treatment.
Objective To describe a new adverse event occurring during anti–PD-1/anti–PD-L1 therapy for LC.
Design, Setting, and Participants A case series from a descriptive observation of 14 patients with HR after anti–PD-1/anti–PD-L1 treatment, recruited between September and December, 2016, who were followed up to detect whether they developed cutaneous AE at the time HR was detected. The patients had all been treated in the dermatology department at Hospital Universitari Germans Trias i Pujol, Badalona, Spain.
Main Outcomes and Measures Clinical observation of HR during anti–PD-1/anti–PD-L1 therapy for LC, proved by comparing old pictures provided by the patients and recent pictures taken during the follow-up.
Results Fourteen patients (13 men and 1 woman; mean age, 64.9 years) receiving anti–PD-1 or anti–PD-L1 therapy for non–small-cell lung cancer (NSCLC) presented hair repigmentation during follow-up. This hair repigmentation consisted in a diffuse darkening of the hair in 13 of 14 patients, or in black patches between white hairs in 1. Thirteen of 14 patients presented a good clinical response to the treatment, with at least stable disease, and only 1 had to stop the therapy after only 4 cycles of treatment owing to a life-threatening progression of the disease.
Conclusions and Relevance We present to our knowledge the first report of hair repigmentation owing to anti–PD-1/anti–PD-L1 therapy for lung cancer in a series of 14 patients. Hair repigmentation may be a good response marker in patients receiving anti-PD1/anti–PD-L1 therapy for LC.

www.leafscience.org/wp-content/uploads/2017/08/Capture.jpg
 
  • +1
Reactions: Deleted member 6401
Why would you take immunosuppressants for you HAIR. that's idiotic man who would trade his health to change his hair color?

I mean graying>>>>>>balding, and you can look great with gray hair
 
  • +1
Reactions: Deleted member 1973 and Deleted member 6401

Similar threads

URL code
Replies
5
Views
138
URL code
URL code
irrumator praetor
Replies
89
Views
3K
mefrom
mefrom
Seth Walsh
Replies
11
Views
544
Rollie Pollie
R
FBl
Replies
13
Views
353
FBl
FBl

Users who are viewing this thread

Back
Top